REPLY: We thank Martínez-Duncker and Hurtado-López for their comments about our paper on 18F-FDG PET in thyroid nodules with inconclusive cytologic results (1). We agree with them that several other radiopharmaceuticals besides 18F-FDG PET can be considered for evaluation of solitary thyroid nodules. They refer to their recent paper on the use of 99mTc-MIBI for this purpose (2). Like 18F-FDG PET, 99mTc-methoxyisobutylisonitrile (MIBI) was positive in all patients with thyroid cancer (1,2). For 18F-FDG PET, this is in line with data in the literature (3,4). However, several studies in the literature do report false-negative 99mTc-MIBI findings in thyroid cancer (5,6).
Furthermore, their study (2) was designed differently from ours (1). First, 78 of 130 patients (60%) underwent diagnostic fine-needle aspiration biopsy (FNAB). These patients do not require any additional imaging—neither 18F-FDG PET nor 99mTc-MIBI. This type of group was not included in our study. The remaining 52 patients (40%) had inconclusive FNAB results (2). This is a relatively large percentage of patients, because inconclusive aspirates typically are reported in up to 20% of cases (7,8). The number of patients in the inconclusive-FNAB group who ultimately had thyroid cancer was also relatively high (18/52, or 35%) (2), whereas approximately 20% is typical (9). In our series, the prevalence of thyroid cancer was 14% (1).
When they separately analyzed the results of 99mTc-MIBI imaging in the 52 patients with inconclusive FNAB results (2), 20 of 52 patients (38%) showed negative findings on 99mTc-MIBI scintigraphy and were diagnosed with benign disease. In our study (1), 18F-FDG PET findings were negative in 25 patients (57%), all of whom had benign thyroid nodules.
In conclusion, 18F-FDG seems to be less prone to accumulation in benign thyroid nodules than is 99mTc-MIBI, thereby allowing better selection of patients with inconclusive FNAB results who require surgical intervention. Furthermore, unlike 18F-FDG PET, the literature contains evidence that false-negative 99mTc-MIBI findings do occur in thyroid cancer. For these reasons, we do not support the recommendation of Martínez-Duncker and Hurtado-López that 99mTc-MIBI scans should be the first study performed in the diagnostic algorithm of patients with thyroid nodules and inconclusive cytologic results to avoid unnecessary thyroid surgery. However, a definite conclusion in favor of either 18F-FDG PET or 99mTc-MIBI can be drawn only in a prospective comparative study with appropriately selected patients, especially in view of the high percentage of inconclusive FNAB results and the high prevalence of thyroid cancer in their series (2).
Footnotes
-
COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.